Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

David Bond

David Bond

MD
The Ohio State University Comprehensive Cancer Center
Increasing the efficacy of PD-1 inhibitors in HL using combination strategies 1:06
Increasing the efficacy of PD-1 inhibitors in HL using combination strategies
David Bond • 16 Jun 2023
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma 1:15
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
David Bond • 16 Jun 2023
Evaluating the combination of nivolumab and lenalidomide in relapsed HL and LBCL 2:29
Evaluating the combination of nivolumab and lenalidomide in relapsed HL and LBCL
David Bond • 16 Jun 2023
The content of VJHemOnc is intended for healthcare professionals